ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

ClinicalTrials.gov ID: NCT03587272

Public ClinicalTrials.gov record NCT03587272. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT03587272
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Robert Nickel
Other
Enrollment
100 participants

Conditions and interventions

Interventions

  • Alemtuzumab, low dose total body irradiation, Sirolimus Drug

Drug

Eligibility (public fields only)

Age range
2 Years to 25 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 16, 2018
Primary completion
Oct 31, 2030
Completion
Oct 31, 2030
Last update posted
Mar 9, 2026

2018 – 2030

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
Children's National Health System Washington D.C. District of Columbia 20010 Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois 60611 Recruiting
Columbia University New York New York 10032 Recruiting
Levine Children's Hospital Charlotte North Carolina 28203 Recruiting
Nationwide Children's Hospital Columbus Ohio 43205 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03587272, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 9, 2026 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03587272 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →